Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19768617 | 1.00 | LMNA (0.36) | LMNAALDH1A1USP2MAPTHSD17B10 | |
| SCHEMBL19768603 | 1.00 | LMNA (0.36) | LMNAALDH1A1USP2MAPTHSD17B10 | |
| SCHEMBL19768569 | 0.82 | LMNA (0.33) | LMNAALDH1A1USP2MAPTHSD17B10 | |
| SCHEMBL19768601 | 0.77 | ALDH1A1 (0.36) | LMNAALDH1A1USP2MAPTHSD17B10 | |
| SCHEMBL17973311 | 0.77 | ALDH1A1 (0.36) | LMNAALDH1A1USP2MAPTHSD17B10 | |
| SCHEMBL17964310 | 0.77 | ALDH1A1 (0.36) | LMNAALDH1A1USP2MAPTHSD17B10 | |
| SCHEMBL19768607 | 0.76 | — | — | |
| SCHEMBL21540727 | 0.71 | TSHR (0.32) | LMNAALDH1A1TSHRCYP3A4CYP2C9 | |
| SCHEMBL19768588 | 0.71 | TSHR (0.32) | LMNAALDH1A1TSHRCYP3A4CYP2C9 | |
| SCHEMBL17964260 | 0.71 | TSHR (0.32) | LMNAALDH1A1TSHRCYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180016221-A1 | SPIROFURANONE COMPOUNDS, DERIVATIVES THEREOF AND PROCESSES FOR THEIR PREPARATION | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2018-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016221-A1 | SPIROFURANONE COMPOUNDS, DERIVATIVES THEREOF AND PROCESSES FOR THEIR PREPARATION | PKD1, PKD2, DHPS | LMNA 427/4885ALDH1A1 532/4885USP2 4881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.